Inventiva (NASDAQ:IVA) Coverage Initiated by Analysts at Barclays

Barclays initiated coverage on shares of Inventiva (NASDAQ:IVA) in a report published on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $18.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price target on shares of Inventiva in a research note on Tuesday, September 30th. Guggenheim dropped their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. HC Wainwright set a $24.00 price target on shares of Inventiva and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. Finally, UBS Group started coverage on Inventiva in a report on Wednesday, January 7th. They set a “buy” rating and a $12.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $16.22.

Inventiva Trading Down 6.1%

NASDAQ:IVA traded down $0.42 during trading hours on Tuesday, reaching $6.42. 292,871 shares of the stock were exchanged, compared to its average volume of 635,313. Inventiva has a 52 week low of $2.23 and a 52 week high of $7.98. The firm has a 50 day simple moving average of $4.96 and a 200-day simple moving average of $4.77.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning bought a new stake in shares of Inventiva during the second quarter worth $32,000. Wealth Enhancement Advisory Services LLC raised its holdings in Inventiva by 54.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after purchasing an additional 5,843 shares during the last quarter. NewEdge Advisors LLC acquired a new position in Inventiva during the 3rd quarter valued at about $116,000. Finally, Millennium Management LLC bought a new position in shares of Inventiva in the 3rd quarter valued at about $649,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.